Skip to main content

Table 5 Association with immune markers, grade and stage

From: Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

  No. Patients n (%) with stage III-IV P-value n (%) with grade 3 P-value
Overall 55 46 (83.6)   41/54 (75.9)  
aPresence with CD3      
 T-PD-1 + CD3 44 35 (79.5) 0.18 31 (72.1) 0.26
 S-PD-1 + CD3 43 34 (79.1) 0.18 34 (81.0) 0.13
 Combined PD-1 + CD3 47 38 (80.9) 0.33 34 (73.9) 0.66
 PD-L1 + CD3 18 13 (72.2) 0.13 17 (94.4) 0.040
Presence with FoxP3      
 T-PD-1 + FoxP3 41 33 (80.5) 0.42 30 (75.0) 0.99
 S-PD-1 + FoxP3 41 33 (80.5) 0.42 33 (82.5) 0.075
 Combined PD-1 + FoxP3 44 36 (81.8) 0.67 33 (76.7) 0.99
 PD-L1 + FoxP3 18 13 (72.2) 0.13 17 (94.4) 0.040
  1. aEvaluation of the association of the presence of PD-1 or PD-L1 together with CD3 and FoxP3 T cells on advanced disease and on high grade tumors. Significant P-values are indicated in italics